The Future of Longevity: How PNOĒ is Democratizing Clinical-Grade Metabolic Testing

At first glance, the newest device from the health-tech startup PNOĒ looks like something plucked from the wardrobe department of a dystopian thriller. The mask—which covers the nose and mouth, cinching securely around the back of the head—bears a striking resemblance to the iconic face-gear worn by the DC Comics villain Bane. Yet, while the aesthetic may be intimidating, the intent is profoundly life-affirming.

PNOĒ’s hardware is designed to measure the invisible mechanics of human health: how much oxygen you consume and how much carbon dioxide you exhale. By converting this respiratory data into actionable insights on nutrition, exercise, and metabolism, the company aims to move health tracking from the realm of speculative fitness metrics into the precision of clinical diagnostics. As the wellness industry pivots toward “longevity” as its primary North Star, PNOĒ is positioning itself as the essential, data-driven scorecard for the modern human.

The Evolution of Metabolic Insight

Metabolic testing is not a new science; it has been the gold standard in elite sports medicine and hospital labs for over a century. By analyzing the gases in a person’s breath, clinicians can determine how the body produces energy, providing a granular look at cardiorespiratory health. Traditionally, however, these tests required "metabolic carts"—bulky, expensive machines that confined testing to university research labs or high-end sports performance centers.

For the last ten years, PNOĒ has sought to shrink this technology without sacrificing its accuracy. With the upcoming October 1 launch of the PNOĒ 2.0, the company is attempting its most ambitious leap yet: self-administration.

"Someone can walk into a gym, just wear the mask, push the button, sit down, and breathe for eight minutes," says Apostolos Atsalakis, co-founder and CEO of PNOĒ. "That’s it. It’s that easy."

This ease of use marks a departure from the company’s first-generation device, which required a trained operator to facilitate the test. By removing the need for a technician, PNOĒ is effectively opening the door for its technology to enter mainstream fitness centers, boutique studios, and eventually, pharmacies.

Chronology: From Cambridge Labs to Global Scale

The genesis of PNOĒ dates back to the University of Cambridge, where Atsalakis was completing his PhD in sensing technologies. During a time when the wearable tech boom was in its infancy, Atsalakis became fascinated by the untapped potential of human breath. He observed that while smartwatches were excellent at tracking heart rate, they were essentially guessing at metabolic efficiency.

Atsalakis teamed up with his childhood friend, Panos Papadiamantis, who now serves as the company’s Chief Product Officer. The pair set out to bridge the gap between "guesswork" fitness trackers and clinical metabolic carts.

• 2019: PNOĒ joins the prestigious Y Combinator winter cohort, entering the ecosystem just as the "longevity" industry began to gain momentum.
• Post-2019: The company secures a total of $22 million in funding, including a recent $11 million round led by investors such as 50 Years and Google Maps co-founder Lars Rasmussen.
• Present Day: PNOĒ now employs 110 people across its Malden, Massachusetts headquarters and its primary operations hub in Athens, Greece. The company has officially turned profitable and reports a year-over-year growth rate exceeding 100%.
• October 1, 2024: The scheduled launch of the PNOĒ 2.0, representing the company’s move toward a more compact, self-service model.

Data Points: What 23 Biomarkers Reveal

The core value proposition of PNOĒ lies in its data density. While an Apple Watch or a Garmin device might provide a rough estimate of VO2 max (the maximum amount of oxygen the body can utilize during intense exercise) based on heart-rate correlation, PNOĒ measures it directly.

The device captures 23 distinct biomarkers, providing a comprehensive "metabolic profile." Key metrics include:

• Resting Metabolic Rate (RMR): The precise number of calories the body burns while at rest, offering a clearer picture for weight management than generic online calculators.
• Metabolic Flexibility: A critical metric that indicates how efficiently the body switches between burning fat and carbohydrates for fuel.
• Ventilatory Thresholds: These data points help athletes and wellness enthusiasts determine exactly at what intensity their body shifts from aerobic to anaerobic energy production.

Atsalakis argues that these metrics resolve questions that even the most comprehensive blood tests cannot answer. "A blood test tells you what is in your body at a single moment in time," he explains. "Our test tells you how your body is actually functioning under load."

The "Business in a Box" Model

PNOĒ does not sell its hardware directly to consumers. Instead, it operates a B2B model, selling a subscription package to high-end fitness clubs, luxury hotel chains, and med-spas. Clients include fitness giant Equinox, the Four Seasons, Red Bull, the NBA, and the Mount Sinai Health System.

The company provides a "business in a box" service, charging between $400 and $1,000 per month. This fee includes the hardware, software, comprehensive training for staff, and marketing materials. This allows a gym or a wellness retreat to offer a "clinical-lite" experience to their members, effectively turning a standard training session into a guided, data-backed health journey.

By utilizing a modular design—where the high-end electronics detach from the silicone mask and straps—PNOĒ has solved the hygiene concerns of a post-pandemic world. Each user keeps their own personalized mask, while the expensive internal hardware remains shared, keeping the cost to businesses manageable.

Regulatory Caution and Future Implications

Despite its clinical capabilities, PNOĒ maintains a careful stance regarding its legal standing. The device is not currently FDA-cleared for medical diagnosis, and the company is explicit in its marketing: it is a wellness tool, not a medical device.

"We do not provide medical recommendations," Atsalakis notes. "It’s like a body composition device—like a scale. A doctor cannot prescribe medication based on our results."

This regulatory restraint is a strategic choice, though one that may evolve. Researchers are currently exploring whether breath analysis could eventually detect early-stage cancer or metabolic diseases. Atsalakis acknowledges that while the company is sitting on a "growing trove of data," full-scale diagnostic approval is likely several years away.

The Competitive Landscape

PNOĒ sits in a unique middle ground. On the low end, consumer-grade wearables offer continuous, passive monitoring but lack the precision of direct gas exchange measurement. On the high end, clinical metabolic carts remain the gold standard but are prohibitively expensive and logistically difficult to manage.

As the longevity movement gains mainstream appeal—driven by influencers and researchers who view VO2 max as the single strongest predictor of mortality—the demand for this "middle ground" is skyrocketing. PNOĒ is banking on the fact that as people become more obsessed with their health data, they will inevitably seek more precise answers than a wrist-worn sensor can provide.

Conclusion: Putting the Mask on the World

With its Series B funding round expected within the next six to 12 months, PNOĒ is preparing to scale its footprint globally. The company is currently expanding its presence in Europe, Latin America, and Asia, aiming to standardize the way we measure human performance.

Whether or not the "Bane mask" look will hinder widespread adoption remains to be seen. However, as the quest for longevity moves from the fringes of biohacking into the daily routines of the average fitness enthusiast, PNOĒ is well-positioned to become the industry’s primary validator. By turning complex respiratory science into a seamless, eight-minute experience, the company is not just selling a device; it is selling the ability to see the body’s inner workings with unprecedented clarity.